Silica Corpora
Company Overview
Silica Corpora is a biotechnology company founded in 2022, focused on transforming drug discovery through advanced AI-driven antibody design technology.
Technology and Mission
Silica Corpora leverages a proprietary AI-based platform specializing in de novo antibody design and optimization targeting priority diseases. Their modular system uses AI, machine learning, and data analytics to design and generate therapeutic antibody candidates from amino acid sequences with high efficiency, precision, and control. The platform includes various modules such as Generator, Discriminator, Optimizer, and Ep-Mapper to develop novel antibodies and optimize their properties for improved drug candidates.
The company's mission is to develop advanced de novo solutions that enhance the quality and cost-effectiveness of antibody therapeutics for diseases with high unmet medical needs, reducing time and cost in drug discovery and development.
Leadership and Collaborations
Silica Corpora was founded by Tim Ermak and Jaime Rosselló, with Anna-Catharina Krebs joining in 2023 as Chief Scientific Officer to accelerate development. The company has strategic partnerships with institutions such as Berkeley Skydeck, SIB, Charité, Google Cloud, Exist, 5HT, Fraunhofer, and others to drive innovation and expand impact.
